Recent advances in treating extra-ocular lymphomas

References

• Verdijk RM. Lymphoproliferative tumors of the Ocular adnexa. Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa). 2017;6(2):132–142.
   PubMed Web of Science ®Google Scholar
• Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972;29(1):252–260.
   PubMed Web of Science ®Google Scholar
• Ferry JA, Fung CY, Zukerberg L, et al. Lymphoma of the ocular adnexa: A study of 353 cases. Am J Surg Pathol. 2007;31(2):170–184.
   PubMed Web of Science ®Google Scholar
• Swerdlow SHCE, Harris NL, Jaffe ES, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th Edition. Lyon: IARC; 2017.
   Google Scholar
• AJCC Cancer Staging. Manual. 8th ed. Springer International Publishing, Switzerland. 2016.
   Google Scholar
• Svendsen FH, Heegaard S. Lymphoma of the eyelid. Surv Ophthalmol. 2016;26(3):312–331.
   Google Scholar
• Graue GF, Finger PT, Maher E, et al. Ocular adnexal lymphoma staging and treatment: american joint committee on cancer versus ann arbor. Eur J Ophthalmol. 2013;23(3):344–355.
   PubMed Web of Science ®Google Scholar
• Heegaard S, Chevez-Barrios P, White V, et al. Ocular adnexal lymphoma. In: Amin M, editor. AJCC cancer staging manual. 8th. Springer International Publishing, Switzerland. 2017.
   Google Scholar
• Kirkegaard MM, Coupland SE, Prause JU, et al. Malignant lymphoma of the conjunctiva. Surv Ophthalmol. 2015;60(5):444–458.
   PubMed Web of Science ®Google Scholar
• Stannard C, Sauerwein W, Maree G, et al. Radiotherapy for ocular tumours. Eye . 2013;27(2):119–127. (London, England).
   PubMed Web of Science ®Google Scholar
• Kirkegaard MM, Rasmussen PK, Coupland SE, et al. Conjunctival lymphoma–an international multicenter retrospective study. JAMA Ophthalmol. 2016;134(4):406–414.
   PubMed Web of Science ®Google Scholar
• Munch-Petersen HD, Rasmussen PK, Coupland SE, et al. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study. JAMA Ophthalmol. 2015;133(2):165–173.
   PubMed Web of Science ®Google Scholar
• Svendsen FH, Rasmussen PK, Coupland SE, et al. Lymphoma of the eyelid - an international multicenter retrospective study. Am J Ophthalmol. 2017;177:58–68.
   PubMed Web of Science ®Google Scholar
• Decaudin D, De Cremoux P, Vincent-Salomon A, et al. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood. 2006;108(5):1451–1460.
   PubMed Web of Science ®Google Scholar
• Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2015;92(1):11–31.
   PubMed Web of Science ®Google Scholar
• Pinnix CC, Dabaja BS, Milgrom SA, et al. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2017;39(6):1095–1100.
   PubMed Web of Science ®Google Scholar
• Fukutsu K, Kase S, Ishijima K, et al. The clinical features of radiation cataract in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma. Radiat Oncology. 2018;13(1):95. (London, England).
   PubMedGoogle Scholar
• Goyal S, Cohler A, Camporeale J, et al. Intensity-modulated radiation therapy for orbital lymphoma. Radiat Med. 2008;26(10):573–581.
   PubMedGoogle Scholar
• Fasola CE, Jones JC, Huang DD, et al. Low-dose radiation therapy (2 Gy x 2) in the treatment of orbital lymphoma. Int J Radiat Oncol Biol Phys. 2013;86(5):930–935.
   PubMed Web of Science ®Google Scholar
• Fuji H, Yoshikawa S, Kasami M, et al. High-dose proton beam therapy for sinonasal mucosal malignant melanoma. Radiat Oncology. 2014;9:162. (London, England)
   PubMed Web of Science ®Google Scholar
• Durkin SR, Roos D, Higgs B, et al. Ophthalmic and adnexal complications of radiotherapy. Acta Ophthalmol Scand. 2007;85(3):240–250.
   PubMedGoogle Scholar
• Regueiro CA, Valcarcel FJ, Romero J. de la Torre A. Treatment of conjunctival lymphomas by beta-ray brachytherapy using a strontium-90-yttrium-90 applicator. Clin Oncol (R Coll Radiol). 2002;14(6):459–463.
   PubMed Web of Science ®Google Scholar
• Oellers P, Savar A, Samaniego F, et al. Second-line 90Yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab. Ophthal Plast Reconstr Surg. 2012;28(6):e145–6.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Broccoli A. Possible novel agents in marginal zone lymphoma. Best Practice & Research Clinical Haematology. 2017;30(1–2):149–157.
   PubMed Web of Science ®Google Scholar
• Decaudin D, Mounier N, Tilly H, et al. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA Phase II Prospective Study. Clinical Lymphoma, Myeloma & Leukemia. 2011;11(2):212–218.
   PubMed Web of Science ®Google Scholar
• Ozyigit G, Cengiz M, Yazici G, et al. Robotic stereotactic body radiotherapy in the treatment of sinonasal mucosal melanoma: report of four cases. Head Neck. 2013;35(3):E69–73.
   PubMed Web of Science ®Google Scholar
• Bianciotto C, Shields CL, Lally SE, et al. CyberKnife radiosurgery for the treatment of intraocular and periocular lymphoma. Arch Ophthalmol. 2010;128(12):1561–1567.
   PubMedGoogle Scholar
• Ben Simon GJ, Cheung N, McKelvie P, et al. Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit. Ophthalmology. 2006;113(7):1209–1213.
   PubMed Web of Science ®Google Scholar
• Svendsen FH, Heegaard S. Lymphoma of the eyelid. Surv Ophthalmol. 2017;62(3):312–331.
   PubMed Web of Science ®Google Scholar
• Ning F, Ye J, Wei LQ, et al. [Efficacy of chemotherapy as a first-line treatment in patients with ocular adnexal MALT lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012;20(4):912–916.
   PubMedGoogle Scholar
• Knudsen MKH, Rasmussen PK, Coupland SE, et al. Clinicopathological features of ocular adnexal mantle-cell lymphoma in an international multicenter cohort. JAMA Ophthalmol. 2017;135(12):1367–1374.
   PubMed Web of Science ®Google Scholar
• Andreasen S, Esmaeli B, Holstein SL, et al. An update on tumors of the lacrimal gland. Asia-Pacific Journal of Ophthalmology . 2017;6(2):159–172. (Philadelphia, Pa).
   PubMed Web of Science ®Google Scholar
• Hong J, Kim SJ, Ahn JS, et al. Treatment outcomes of rituximab plus hyper-CVAD in Korean patients with sporadic burkitt or burkitt-like lymphoma: results of a multicenter analysis. Cancer Research and Treatment: Official Journal of Korean Cancer Association. 2015;47(2):173–181.
   PubMedGoogle Scholar
• Abaza Y, Mk H, Faderl S, et al. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018;93(1):91–99.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13(12):1250–1259.
   PubMed Web of Science ®Google Scholar
• Stenman L, Persson M, Enlund F, et al. Primary orbital precursor T-cell lymphoblastic lymphoma: report of a unique case. Molecular and Clinical Oncology. 2016;5(5):593–595.
   PubMedGoogle Scholar
• Toft N, Birgens H, Abrahamsson J, et al. Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. European Journal of Haematology. 2013;90(5):404–412.
   PubMed Web of Science ®Google Scholar
• Savino G, Battendieri R, Gari M, et al. Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections. J Cancer Res Clin Oncol. 2013;139(7):1251–1255.
   PubMed Web of Science ®Google Scholar
• Sjo LD, Heegaard S, Prause JU, et al. Extranodal marginal zone lymphoma in the ocular region: clinical, immunophenotypical, and cytogenetical characteristics. Invest Ophthalmol Vis Sci. 2009;50(2):516–522.
   PubMed Web of Science ®Google Scholar
• Patrick LB, Mohile NA. Advances in primary central nervous system lymphoma. Curr Oncol Rep. 2015;17(12):60.
   PubMed Web of Science ®Google Scholar
• Cabanillas F, Shah B. Advances in diagnosis and management of diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2017;17(12):783–796.
   PubMed Web of Science ®Google Scholar
• Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Reviews Clin Oncology. 2017;14(7):417–433.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Kolibaba KS, Reeves JA, et al. Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2017;35(31):3538–3546.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Aurer I, Cortelazzo S, et al. Treatment for patients with relapsed/refractory mantle cell lymphoma: european-based recommendations. Leuk Lymphoma. 2018;59(8):1814-1828.
   Google Scholar
• Berg SL, Cairo MS, Russell H, et al. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a children’s oncology group phase I consortium report. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2011;29(3):316–323.
   PubMed Web of Science ®Google Scholar
• Rasmussen PK, Coupland SE, Finger PT, et al. Ocular adnexal follicular lymphoma: a multicenter international study. JAMA Ophthalmol. 2014;132(7):851–858.
   PubMed Web of Science ®Google Scholar
• Blasi MA, Tiberti AC, Valente P, et al. Intralesional interferon-alpha for conjunctival mucosa-associated lymphoid tissue lymphoma: long-term results. Ophthalmology. 2012;119(3):494–500.
   PubMed Web of Science ®Google Scholar
• Cai J, Liu X, Cheng J, et al. MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2. Graefe’s Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie. 2012;250(4):523–531.
   PubMed Web of Science ®Google Scholar
• Baldini L, Blini M, Guffanti A, et al. Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa. Ann Oncology: Official Journal Eur Soc Med Oncol. 1998;9(7):779–781.
   PubMed Web of Science ®Google Scholar
• Ahmed AH, Foster CS, Shields CL. Association of disease location and treatment with survival in diffuse large B-cell lymphoma of the eye and ocular adnexal region. JAMA Ophthalmol. 2017;135(10):1062–1068.
   PubMed Web of Science ®Google Scholar
• Shields CL, Shields JA, Carvalho C, et al. Conjunctival lymphoid tumors: clinical analysis of 117 cases and relationship to systemic lymphoma. Ophthalmology. 2001;108(5):979–984.
   PubMed Web of Science ®Google Scholar
• Benekou K, Montoto S. Role of stem cell transplant in lymphoma in the era of new drugs. Curr Opin Oncol. 2017;29(6):455–459.
   PubMed Web of Science ®Google Scholar
• Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21(1):12–17.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Reviews Clin Oncology. 2018;15(1):47–62.
   PubMed Web of Science ®Google Scholar
• Sassone M, Ponzoni M, Ferreri AJ. Ocular adnexal marginal zone lymphoma: clinical presentation, pathogenesis, diagnosis, prognosis, and treatment. Best Practice & Research Clinical Haematology. 2017;30(1–2):118–130.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Thieblemont C, Gallamini A, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncology: Official Journal Eur Soc Med Oncol. 2013;24(4):857–877.
   PubMed Web of Science ®Google Scholar
• Pfeffer MR, Rabin T, Tsvang L, et al. Orbital lymphoma: is it necessary to treat the entire orbit? Int J Radiat Oncol Biol Phys. 2004;60(2):527–530.
   PubMed Web of Science ®Google Scholar
• Ainsbury EA, Bouffler SD, Dorr W, et al. Radiation cataractogenesis: a review of recent studies. Radiat Res. 2009;172(1):1–9.
   PubMed Web of Science ®Google Scholar
• Raderer M, Kiesewetter B, Ferreri AJ. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J Clin. 2016;66(2):153–171.
   PubMed Web of Science ®Google Scholar
• Salar A, Domingo-Domenech E, Panizo C, et al. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2014;1(3):e104–11.
   PubMed Web of Science ®Google Scholar
• Govi S, Dognini GP, Licata G, et al. Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. Br J Haematol. 2010;150(2):226–229.
   PubMed Web of Science ®Google Scholar
• Zucca E, Bertoni F. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. Blood. 2016;127(17):2082–2092.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Sassone M, Kiesewetter B, et al. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. Ann Oncology: Official Journal Eur Soc Med Oncol. 2015;26(8):1760–1765.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–1265.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncology: Official Journal Eur Soc Med Oncol. 2016;27(suppl 5):v83–v90.
   PubMed Web of Science ®Google Scholar
• Rasmussen PK, Ralfkiaer E, Prause JU, et al. Follicular lymphoma of the ocular adnexal region: a nation-based study. Acta Ophthalmol. 2015;93(2):184–191.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet . 2011;377(9759):42–51. (London, England).
   PubMed Web of Science ®Google Scholar
• Martinelli G, Montoro J, Vanazzi A, et al. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-hodgkin’s lymphoma: a retrospective single-centre study. Hematological Oncology. 2015;33(4):129–135.
   PubMed Web of Science ®Google Scholar
• Casulo C, Friedberg JW, Ahn KW, et al. Autologous transplantation in follicular lymphoma with early therapy failure: a national lymphocare study and center for international blood and marrow transplant research analysis. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2018;24(6):1163-1171.
   PubMed Web of Science ®Google Scholar
• Rasmussen P, Ralfkiaer E, Prause JU, et al. Malignant lymphoma of the lacrimal gland: a nation-based study. Arch Ophthalmol. 2011;129(10):1275–1280.
   PubMedGoogle Scholar
• Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis. Treatment and Follow-Up. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2017;28(suppl_4):iv62–iv71.
   PubMedGoogle Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558–565.
   PubMed Web of Science ®Google Scholar
• Rasmussen P, Sjo LD, Prause JU, et al. Mantle cell lymphoma in the orbital and adnexal region. Br J Ophthalmol. 2009;93(8):1047–1051.
   PubMed Web of Science ®Google Scholar
• Rule S, Dreyling M, Goy A, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179(3):430–438.
   PubMed Web of Science ®Google Scholar
• Shipp MA. A predictive model for aggressive non-hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–994.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008;105(36):13520–13525.
   PubMed Web of Science ®Google Scholar
• Fields PA, Townsend W, Webb A, et al. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2014;32(4):282–287.
   PubMed Web of Science ®Google Scholar
• Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339(1):21–26.
   PubMed Web of Science ®Google Scholar
• Dunleavy K. Aggressive B cell lymphoma: optimal therapy for myc-positive, double-hit, and triple-hit DLBCL. Curr Treat Options Oncol. 2015;16(12):58.
   PubMed Web of Science ®Google Scholar
• Maura F, Guidetti A, Pellegrinelli A, et al. High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression. Blood Cancer J. 2017;7(3):e544.
   PubMedGoogle Scholar
• Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103(10):3684–3688.
   PubMed Web of Science ®Google Scholar
• Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP–an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 1994;12(6):1169–1176.
   PubMed Web of Science ®Google Scholar
• Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71(1):117–122.
   PubMed Web of Science ®Google Scholar
• Rasmussen PK, Ralfkiaer E, Prause JU, et al. Diffuse large B-cell lymphoma of the ocular adnexal region: a nation-based study. Acta Ophthalmol. 2013;91(2):163–169.
   PubMed Web of Science ®Google Scholar
• Wilson ME, Thornton S, Murchison AP, et al. Clinical challenge: an orbital Hickam’s dictum. Surv Ophthalmol. 2016;61(6):799–805.
   PubMed Web of Science ®Google Scholar
• Routledge DJ, Bloor AJ. Recent advances in therapy of chronic lymphocytic leukaemia. Br J Haematol. 2016;174(3):351–367.
   PubMed Web of Science ®Google Scholar
• Shustik C, Bence-Bruckler I, Delage R, et al. Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. Ann Hematol. 2017;96(7):1185–1196.
   PubMed Web of Science ®Google Scholar
• Mato AR, Thompson MC, Nabhan C, et al. Chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia: a narrative review. Clin Lymphoma Myeloma Leuk. 2017;17(12):852–856.
   PubMed Web of Science ®Google Scholar
• Mato A, Porter DL. A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs. Blood. 2015;126(4):478–485.
   PubMed Web of Science ®Google Scholar
• Carmody J, Misra RP, Langford MP, et al. Orbital sporadic burkitt lymphoma in an adult diabetic African American female and a review of adult orbital cases. Clinical Ophthalmology . 2011;5:509–515. (Auckland, NZ)
   PubMedGoogle Scholar
• Casulo C, Friedberg J. Treating burkitt lymphoma in adults. Curr Hematol Malig Rep. 2015;10(3):266–271.
   PubMed Web of Science ®Google Scholar
• Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 1996;14(3):925–934.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with burkitt’s lymphoma. N Engl J Med. 2013;369(20):1915–1925.
   PubMed Web of Science ®Google Scholar
• Treon SP, Castillo JJ. What should be the goal of therapy for waldenstrom macroglobulinemia patients? Complete response should be the goal of therapy. Blood Advances. 2017;1(25):2486–2490.
   PubMed Web of Science ®Google Scholar